New hope for Late-Stroke patients: drug trial uses advanced imaging to guide treatment
NCT ID NCT07379190
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether the drug tirofiban can help people who have had a stroke but missed the usual treatment window (more than 24 hours after symptoms start). The study uses a special MRI scan to select patients whose stroke is caused by a specific type of artery blockage. 458 participants will receive either tirofiban or standard anti-clot drugs, and researchers will measure how well they recover over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tirofiban
What this could lead to
If successful, this could provide a new treatment option for stroke patients who miss the standard treatment window, potentially improving their recovery and reducing disability.
What could go wrong
This is a Phase 3 trial, but it's still early to know if tirofiban is truly better than standard care. There is a risk of bleeding, and the results may not apply to all stroke types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STROKE ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Weifang People's Hospital
RECRUITINGWeifang, China/Shandong Province, 261000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••